Immunotherapy using either checkpoint blockade or the adoptive transfer of antitumor lymphocytes has shown effectiveness in treating cancers with high levels of somatic mutations-such as melanoma, smoking-induced lung cancers and bladder cancer-with little effect in other common epithelial cancers that have lower mutation rates, such as those arising in the gastrointestinal tract, breast and ovary [1] [2] [3] [4] [5] [6] [7] . Adoptive transfer of autologous lymphocytes that specifically target proteins encoded by somatically mutated genes has mediated substantial objective clinical regressions in patients with metastatic bile duct, colon and cervical cancers [8] [9] [10] [11] . We present a patient with chemorefractory hormone receptor (HR)-positive metastatic breast cancer who was treated with tumor-infiltrating lymphocytes (TILs) reactive against mutant versions of four proteins-SLC3A2, KIAA0368, CADPS2 and CTSB. Adoptive transfer of these mutant-protein-specific TILs in conjunction with interleukin (IL)-2 and checkpoint blockade mediated the complete durable regression of metastatic breast cancer, which is now ongoing for > 22 months, and it represents a new immunotherapy approach for the treatment of these patients.
A 49-year-old woman with estrogen receptor (ER)-positive and ERB-B2 receptor tyrosine kinase 2 (ERBB2; also known as HER2)-negative metastatic breast cancer that was refractory to multiple lines of chemotherapy was enrolled in a clinical trial, NCT01174121, designed to determine the ability of autologous tumor-infiltrating lymphocytes (TILs) to mediate tumor regression in patients with metastatic epithelial cancers. Whole-exome sequencing (WES) and RNA sequencing (RNA-seq) of a right breast subcutaneous lesion revealed the presence of 62 nonsynonymous somatic mutations (Supplementary Table 1 ). This mutation burden fell within the interquartile range (IQR 30-95.5, median 47) of a published cohort of 140 patients with HR + HER2 -metastatic breast cancer, whereas primary luminal A breast cancers, generally ER + HER2 -, harbor fewer mutations (IQR 26-39.5, median 32) [12] [13] [14] . TIL fragments lymphocyte populations derived from culturing small pieces of the patient's tumor in high-dose IL-2 (Supplementary Table 2) were initially screened against all of the mutations by using pulsed peptide pools (PPs 1-6) or transfected mRNAs (tandem minigenes (TMGs) [1] [2] [3] [4] [5] [6] expressed in autologous antigen-presenting cells (APCs). TIL fragments F8 and F12 showed reactivity against PP1 but not the corresponding TMG1 (Fig. 1a,b) . TIL F13 showed reactivity against both peptide pool PP6 and TMG6 (Fig. 1a,b) . Individual peptide screens of the TIL fragments showed F8 and F12 recognized the solute carrier family 3 member 2 (SLC3A2) protein (Fig. 1c) . Due to alternative splicing, a variant in the SLC3A2 gene produced three separate peptides, in which each contained the same mutation (p.lysine> threonine) but different C terminal regions (Supplementary Table 1 ). All three SLC3A2 peptides were recognized by F8 and F12 TILs (Fig. 1c) . The reactive F13 TIL recognized mutant ECM29 proteasome adaptor and scaffold (ECPAS; also known as KIAA0368) (Fig. 1d ). SLC3A2 and KIAA0368 reactivity was mediated by CD4 + and CD8
+ T cells, respectively (Fig. 1e ,f and data not shown). To identify neoantigen-reactive T cell clonotypes, mutant-peptide-reactive cells were sorted on the basis of the T cell receptor (TCR)-β variable (TRBV) region or high expression levels of 4-1BB (CD137, a marker of T cell activation) and then subjected to singlecell sequencing. TILs from reactive fragments (F12 and F13) were FACS-sorted by individual TRBV family-member-specific antibodies and stimulated with APCs loaded with mutant (mut)-SLC3A2 or mutKIAA0368. TCR-focused deep sequencing of the sorted cells identified an oligoclonal population of TCR-encoding sequences, with two dominant TRBV (TRBV19-01 and TRBV05-01) and three dominant TCR-α variable (TRAV) sequences (TRAV08-06, TRAV38-01 and TRAV02-01) ( Supplementary Fig. 1a ). Of the six tested TCR pairs, two TCRs (TRBV19-01-TRAV02-01 (TCR K) and TRBV05-01-TRAV38-01 (TCR L)) recognized mutSLC3A2 as demonstrated by ELISPOT assays for detection of IFN-γ -producing cells ( Supplementary Fig. 1b ) and upregulation of 4-1BB ( Fig. 1g and data not shown). In addition, a single KIAA0368-reactive TCR clonotype was identified (TRAV21-01-TRBV06-05) ( Fig. 1h and Supplementary Fig. 1b,c) . Alternatively, 4-1BB hi cells were sorted for single-cell sequencing. Five additional mutSLC3A2-specific TCR pairs were identified (Supplementary Table 3 ). No new mutKIAA0368-reactive TCRs were identified. In total, seven mutSLC3A2-reactive TCRs demonstrated specific and highly avid recognition of mutSLC3A2 to concentrations as low as 10 ng/ml ( Supplementary Fig. 2a ). The response was human leukocyte antigen (HLA)-DRB1*07:01-restricted, and the minimal epitope was located within the amino acid sequence, DPPALASTNAEVT ( Supplementary Fig. 2b-f) . The mutKIAA0368-reactive TCR, TRBV06-05-TRAV21-01 (TCR R), recognized the mut-KIAA0368 peptide at concentrations as low as 100 ng/ml (Fig. 1h Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer (DMSO)   PP1   PP2   PP3   PP4   PP5   PP6   TIL fragment   F8  F12  F13   0   100   200   300   400   Vehicle (H20)   TMG1   TMG2   TMG3   TMG4   TMG5   TMG6 D 
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Mutant peptides from PP1 In e and f, cells were gated on CD3, and data are representative of at least three independent experiments. g, Flow cytometry analysis of allogeneic T cells that were transduced with the sequences encoding TCR K, which specifically recognized the 18-mer mutSLC3A2 peptide (amino acid sequence LLASSDPPALASTNAEVT), as shown by upregulation of 4-1BB. These results are representative of all seven TCRs that were found to specifically recognize the mutSLC3A2 peptide. h, Flow cytometry analysis of allogeneic T cells that were transduced with sequences encoding TCR R, which specifically recognized the 25-mer mutKIAA0368 (p.Ser186Phe) peptide, as shown by upregulation of 4-1BB. In g and h, cells were gated on CD3, and data are representative of two independent experiments. WT, wild type.
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and Supplementary Fig. 3a ). In addition, Vβ 13.1 + (TRBV06-05, TRBV06-06 and TRBV06-09)-sorted F13 TILs specifically recognized TMG6-electroporated APCs, demonstrating that the mutKIAA0368 protein was efficiently processed and presented ( Supplementary Fig. 3b ). The CD8 + mutKIAA0368-specific TCR recognized the predicted epitope (10-mer, MPYGYVLNEF, rank 0.06, 9.5 nM), which was restricted by HLA-B*35:01 ( Supplementary Fig. 3c,d) .
The patient was treated with 8.2 × 10 10 TILs as described in Fig. 2a . The infused cells were predominantly CD4 + (62.5%), with an effector memory (CD62L -CD45RO + ) phenotype. The infusion product maintained its reactivity to mutSLC3A2 and mutKIAA0368 after rapid expansion of the T cells from the fragments (Fig. 2b) , and approximately 21% of the infused CD3
+ cells expressed programmed cell death 1 (PD-1). At the first evaluable time point, 6 weeks after cell transfer, we found that the target tumor burden had reduced 51%; at the most recent evaluation (22 months after cell transfer), all target and nontarget lesions have radiographically resolved (Fig. 2c) .
To assess the potential influence of pembrolizumab, an anti-PD-1 monoclonal antibody, on the patient's tumors, retrospective analysis for the expression of PD-1 and one of its ligands, PD-L1, was performed on two tumor samples obtained before adoptive cell transfer. Biopsy of a chest wall lesion that was refractory to multiple treatments demonstrated one small focal area of CD3
+ cells with no expression of PD-L1 on the tumor or stroma (Fig. 2d, top) . This tumor regressed following adoptive cell transfer. The tumor resected as the source of TILs was a rapidly growing right breast lesion and found to have abundant CD3
+ PD-1 + intratumoral T cells with PD-L1 + stroma; however, there was no evidence of PD-L1 expression on the tumor cells (Fig. 2d, bottom) . PD-1 expression in peripheral blood was 11.4% of CD3 + cells at 6 weeks after transfer, and it remained relatively constant at later time points-9% of CD3
+ cells (at 9 months after transfer) and 7.9% of CD3 + cells (at 2 years after transfer).
TCR-focused deep sequencing of the infused cell population showed that the unique TRBV complementarity determining region 3 (CDR3)-encoding sequences of the eight mutation-reactive clonotypes (seven SLC3A2-reactive and one KIAA0368-reactive TCRs) accounted for 23.1% of the productive sequences at the time of the cell transfer (Fig. 3a) . Evaluation of the peripheral blood 6 weeks after cell transfer revealed that these known mutant-protein-reactive TCRs persisted at a level of 1.73% of all productive TRBV sequences. Additional analysis showed three TRBV families (TRBV07, 12.41%; TRBV20, 13.56%; TRBV28, 16.54%) had significant expansion in the blood at 6 weeks after transfer, with TRBV20 and TRBV28 containing at least one dominant TCR clonotype (β -chain CDR3: CSASDGSTTGSTYEQYF, 11.4%; and CDR3: CASRPPGYEQYF, 5.4%, respectively) of unknown reactivity (Fig. 3b) . TRBV20 + -sorted cells were nonreactive against the peptide pools, TMGs and peptides from cytomegalovirus (CMV), Epstein-Barr virus (EBV) and influenza virus (CEF peptides; data not shown). FACS-sorted TRBV28 + cells showed specific recognition of PP6 and TMG6 (Fig. 3c) . The TRBV28
+ cells specifically recognized two mutant proteins: calcium-dependent secretion activator 2 (CADPS2; p.Arg1266His) and cathepsin B (CTSB; p.Asp159His) (Fig. 3d) . Single-cell sequencing revealed a dominant TCR pair, TRBV28-01-TRAV26-01 (TCR J, 82% of all TCR sequences), that specifically recognized mutCADPS2 and was HLA-C*04-01-restricted, and the minimal epitope recognized was the predicted 9-mer, TYDTVHRHL (Fig. 3e,  Supplementary Fig. 4a -c and Supplementary Table 4 ). Two TCR pairs were identified to be reactive specifically to mutCTSB (TCR M and TCR O, both TRBV28-01-TRAV12-01) with unique CDR3 regions (Fig. 3f, Supplementary Fig. 4d and Supplementary Table 4 ). Both CTSB-specific TCRs were HLA class II, DRB1*07:01 restricted, and the minimal epitope was located within the amino acid sequence GYNSYSVSNSEKHIM ( Supplementary Fig. 4e,f) . Repeat analysis of the T cell repertoire in the infusion bag, using ultra-deep sequencing, revealed the presence of the CADPS2-specific and CTSB-specific TCRs (TCR J and TCR M, respectively), at frequencies < 0.001%, whereas the second CTSB-specific TCR (TCR O) was undetectable.
In total, 11 TCR clonotypes recognized the four neoantigens (SLC3A2, KIAA0368, CADPS2 and CTSB) for patient 4136. Only two TCRs, both of which recognized mutSLC3A2 (TRBV7-9-TRAV26-2 (TCR D) and TRBV19-TRAV9-2 (TCR H)) were detectable in peripheral blood prior to treatment (0.003% and 0.002% of all TRBV sequences, respectively). Following the cell infusion, we evaluated the in vivo persistence of known neoantigen-reactive TCRs in the peripheral blood. The median cumulative frequency during weeks 3-12 was 2.83% of the peripheral repertoire, and the known reactive clonotypes comprised 0.81% of the post-infusion repertoire at 17 months after infusion (Fig. 4a) . Eight of the 11 neoantigen-reactive TCRs persisted in the patient's peripheral blood at least 17 months after treatment (Fig. 4b ). In addition, the dominant clonotypes that were identified 6 weeks after transfer persisted.
To better understand the heterogeneity of the nonsynonymous mutations within the patient's tumor, a clonality analysis was performed on the resected tumor DNA. This analysis revealed that 20/62 (32%) mutations were clonal, 37/62 (60%) were subclonal, and 5 (8%) mutations could not be determined. MutSLC3A2 and mutCADPS2 were clonal (cancer cell fraction (CCF): 0.999, each), whereas, mutCTSB and mutKIAA0368 seemed to be subclonal (CCF: 0.669 and 0.489, respectively) ( Fig. 4c) .
This highly personalized therapy identified reactive T cells against multiple HLA-class-I-and HLA-class II-restricted neoantigens that were presented by the autologous tumor, enriching a potentially narrower repertoire of mutant-reactive T cells than bulk TILs alone. Targeting multiple tumor antigens may overcome potential tumor escape mechanisms, such as downregulation of class I molecules or tumor heterogeneity. By screening for reactivity on the basis of nonsynonymous mutations, T cells that recognized other classes of potential neoantigens were deliberately not selected but may have been a component of the infusion product. The post-treatment blood contained an oligoclonal T cell population of unknown specificity, which may or may not have been tumor reactive. It is likely that the expansion of T cells with unknown reactivity resulted from nonspecific homeostatic reconstitution after lymphodepletion, or it may represent epitope spreading with tumor-stimulated clonal expansion to neoantigens not yet identified, potentially triggered or enhanced by checkpoint inhibitor blockade. It has been shown previously that preparative lymphodepletion can create an immune milieu that is primed for lymphocyte expansion, with high circulating levels of IL-7 and IL-15 15 . While the increased homeostatic cytokines can aid the proliferation of infused autologous TILs, it is likely that the entire reconstituting lymphocyte population may compete for these growth factors.
Although limited responses to pembrolizumab treatment have been reported in patients with triple-negative breast cancer (TNBC), there are no published data to support pembrolizumab activity in HR + breast cancer. The biopsies of the chest wall and subcutaneous masses shown in Fig. 2 revealed no expression of PD-L1, suggesting that pembrolizumab treatment likely had minimal to no impact in this patient. In a related clinical trial, 2 of 12 patients, one with bile duct cancer 10 and the other with colon cancer 9 , received mutant-protein-reactive TILs without the administration of pembrolizumab, and both patients underwent objective cancer regressions. On the basis of prior studies, transferred lymphocytes expressed little to no PD-1 at the time of infusion but re-expressed PD-1 1 month after the infusion 16 . Although a portion of this patient's infusion product did express PD-1, the level of PD-1 expression in the peripheral blood remained relatively constant during and after pembrolizumab 
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The rapid identification of mutant-protein-specific TCR sequences by single-cell sequencing may provide a means of engineering neoantigen reactivity into autologous PBLs with a high proliferative potential, which may be more effective than the direct use of TILs.
Metastatic breast cancer can be a heterogeneous disease, and this patient demonstrated that a personalized therapy tailored to target the unique somatic mutations presented by the autologous tumor of the affected individual can mediate complete durable cancer regression. were detected in pre-treatment peripheral blood (denoted by the asterisk) and comprised 0.005% of all CDR3 sequences. The total percentage of reactive clonotypes identified in the peripheral blood was highest at the earliest time point (3.29%), but eight of these clonotypes persisted 17 months after treatment, comprising 0.81% of all CD3 + cells. Clonotypes (of the TRBV20 and TRBV28 families; see Fig. 3b ) of unknown reactivity that dominated the peripheral blood at 6 weeks after transfer persisted as 3.6% of productive CDR3 sequences at 17 months after transfer (data not shown). Sequences corresponding to TCR J were detected only with ultra-deep sequencing of the infusion bag, but TCR J was a dominant intratumoral clonotype that expanded after treatment. b, The pattern of persistence in peripheral blood for each of the eight mutant-reactive clonotypes that persisted at 17 months after transfer. Bars indicate the percentage of infusion product. Rank (in parentheses) indicates relative position of the unique CDR3 sequence when all productive CDR3 sequences are sorted in decreasing frequency. Crossed circles indicate 'not detected' (n.d.) with a cut-off frequency of 0.0005. For the + 1-week and + 3-week samples, the lower limits of detection were 0.0044 and 0.0016, respectively. Rx1, treatment 1. FrTu, fresh tumor. c, Clonal architecture of the resected tumor, with recognized neoantigens identified. The top panel provides a histogram of the density of the nonsynonymous mutations depicted in the bottom panel. a.u., arbitrary units.
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Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0040-8.
14. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 490, 61-70 (2012 . After a short response to nanoparticle-albumin-bound (nab)-paclitaxel treatment, persistent disease was found to be refractory to multiple endocrine therapies and chemotherapies (capecitabine, vinorelbine, docetaxel, doxorubicin and cyclophosphamide), and biopsy (Fig. 2d, top) ) and processed for identification of nonsynonymous somatic mutations in the tumor and for the generation of TILs (Fig. 2d, bottom) . In the 4 months between resection and treatment, the patient received everolimus and demonstrated clinical and radiologic progression before receiving the clinical treatment described below. The patient never received radiation therapy and did not harbor known germline mutations in the BRCA1 and BRCA2 oncogenes, or other known deleterious somatic mutations in highpenetrance genes involved in breast cancer susceptibility.
Treatment and analysis of response. Administration of autologous TILs was defined as day 0. Preparative nonmyeloablative lymphodepleting chemotherapy consisted of cyclophosphamide (60 mg per kg body weight (mg/kg)) and fludarabine (25 mg/m 2 ), which was administered on days -7 and -6, followed by additional doses of fludarabine alone on days -5 to -3. A single dose of pembrolizumab (2 mg/kg) was administered on day -2. On day 0, the patient received an intravenous infusion of 8.2 × 10 10 TILs supported by administration of aldesleukin (720,000 IU/kg) every 8 h to tolerance (seven doses) and pembrolizumab (days + 21, + 42 and + 63). The patient developed transient grade 3 hypophosphatemia and expected grade 4 hematologic cytopenias during preparative chemotherapy. After cell infusion and during the course of IL-2 administration, the patient developed grade 3 febrile neutropenia, which resolved with antibiotic therapy. There were no grade 3 or 4 adverse events during outpatient pembrolizumab administration. There was no evidence of off-target effects on normal tissue. Cross-sectional imaging was performed before treatment and at regular intervals after treatment. Response was monitored using Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 parameters.
Whole-exome sequencing (WES), RNA sequencing (RNA-seq) and determination of mutation clustering. WES and RNA-seq were performed at the Surgery Branch (SB), NCI. Genomic DNA (gDNA) and total RNA was purified from fresh tumor (FrTu) or ten 10-μ m OCT sections and matched normal apheresis samples using the Qiagen AllPrep DNA/RNA kit (Qiagen), as per the manufacturer's suggestions. Whole-exome library construction and exon capture of approximately 20,000 coding genes were done using Agilent Technologies SureSelectXT Target Enrichment System for paired-end libraries coupled with Human All Exon V6 RNA bait (Agilent Technologies). Exome libraries were prepped using 3 µ g gDNA from fresh tumor tissue samples or 200 ng gDNA from the OCT sections, as per the manufacturer's protocol. WES libraries were subsequently sequenced on a NextSeq 500 desktop sequencer (Illumina). Pairedend sequencing was done with an Illumina High-output flow cell kit (300 cycles). The mean sequencing depth for the following samples were: FrTu (118× ), OCT (120× ) and normal blood (116× ). The percentage of tumor in each sample (tumor purity) was 26.6% for both the FrTu and OCT samples, as estimated with the bioinformatics program 'allele-specific copy-number analysis of tumors' (ASCAT). An RNA-seq library was prepared using 2 µ g of total RNA from fresh tumor with the Illumina TruSeq Stranded Total RNA library prep kit, as per the manufacturer's protocol. The RNA-seq library was paired-end-sequenced on a NextSeq 500 desktop sequencer (Illumina). Exome-sequencing alignments were performed using novoalign MPI from novocraft (http://www.novocraft.com/) to human genome build hg19. Duplicates were marked using Picard's MarkDuplicates tool. Insertion and deletion (indel) realignment and base recalibration were performed according to the GATK best-practices workflow (https://www.broadinstitute. org/gatk/). Once data were realigned and recalibrated, samtools (http://samtools. sourceforge.net) was used to create tumor and normal pileup files, and Varscan2 (http://varscan.sourceforge.net) was used to call somatic variants using the following criteria: tumor and normal read counts of 6 or greater, variant-allele frequency (VAF) ≥ 5% and tumor-variant reads ≥ 3. These variants were then annotated using Annovar (http://annovar.openbioinformatics.org).
For RNA-seq, alignments were performed by using the STAR (https:// github.com/alexdobin/STAR) two-pass method to human genome build hg19. Duplicates were marked using Picard's MarkDuplicates tool. Reads were split and trimmed using the GATK SplitNTrim tool, after which indel realignment and base recalibration were performed using the GATK toolbox. A pileup file was created using the final recalibrated bam file and samtools mpileup. Finally, variants were called using Varscan2.
Variants were further selected to increase the confidence of neoantigen identification. Mutations for immunological screening were selected based on their presence in both the tumor exome and the transcriptome, and the RNA variants must have had VAF > 10%, reads > 1. The mutations in patient 4,136 that were used for neoantigen identification are listed in Supplementary Table 1. WES data for patient 4136 were used in the copy-number analysis. The data analysis was performed in the R statistical environment, version 3.3.0. The segmented copy number, cellularity and ploidy were determined using Sequenza v2.1.2, with normal sample as references and hg19 coordinates. The CCF of each mutation was estimated by integrating the local copy number, tumor purity (obtained from Sequenza) and VAF. All mutations with a read depth > 3 and VAF > 5% were clustered using PyClone v1.3.0 Dirichlet process clustering 17 . We ran PyClone with 50,000 iterations and a burn-in of 1,000.
TIL generation. TILs were generated as previously described 18 . Cells from each TIL culture were phenotypically characterized by flow cytometry before cryopreservation, by staining for the CD3, CD4, CD8 and CD56 surface markers. Following the identification of neoantigen-reactive TILs, TIL cultures derived from fragments 8, 12 and 13 were selected for treatment and were expanded into high numbers using a rapid expansion protocol (REP) using IL-2, anti-CD3 antibody (clone OKT3, Miltenyi Biotec) and irradiated feeders 18 . All cells were cultured at 37 °C with 5% CO 2 for 2 weeks before infusion.
Preparation of antigen-presenting cells (APCs) and EBV-B cells for TIL screening. Autologous CD19
+ B cells were sorted from the patient's apheresis sample using anti-CD19 microbeads (Miltenyi Biotec) and cultured with irradiated (6,000 rad) NIH-3T3 cells that stably expressed CD40L (3T3-CD40L, authenticated by FACS for CD40L) at a 1:1 ratio in B cell medium comprised of Iscove's modified Dulbecco's medium (IMDM) (ThermoFisher Scientific) supplemented with 10% human serum and 200 U/ml IL-4 (Peprotech). CD14
+ dendritic cells were sorted and transferred to a T150 flask, incubated with dendritic cell medium (RPMI 1640 medium supplemented with 5% human serum, 2 mM l-glutamine, 800 IU/ml granulocyte-macrophage-colony-stimulating factor (GM-CSF; Peprotech) and 200 U/ml IL-4 (Peprotech)). Partially HLA-DR-matched allogeneic EBV-B cells (authenticated in the Surgery Branch by HLA typing) were grown in R10 medium (RPMI 1640 medium supplemented with 10% fetal bovine serum and 2 mM l-glutamine).
Generation of tandem minigene (TMG) constructs and in-vitro-transcribed (IVT) RNA.
TMGs were constructed as previously described 10 . Twelve minigenes were included in each TMG construct for this study. Plasmids encoding the minigenes were linearized with the restriction enzyme NsiI, and each linearized plasmid was used as a template for in vitro transcription using the mMESSAGE mMACHINE T7 Transcription Kit (ThermoFisher Scientific), as per the manufacturer's instructions.
RNA transfection and peptide-pulsing of autologous antigen-presenting cells. Dendritic or B cells (APCs) were transfected with TMG RNA using the Neon Transfection System (ThermoFisher Scientific), as per the manufacturer's instructions. Briefly, APCs were resuspended in the kit's Resuspension Buffer at a concentration 1 × 10 7 cells/ml. The APCs were mixed with TMG RNA (10 μ g per 1 × 10 6 APCs) just before the electroporation, aspirated into the Neon pipette and electroporated with either '1,500 V, 30 ms and one pulse' for dendritic cells or '1,500 V, 10 ms and three pulses' for B cells in the Neon device (ThermoFisher Scientific). Following electroporation, cells were immediately transferred into 24-or 48-well plates with dendritic cell (D) or B cell medium, respectively, supplemented with the appropriate cytokines and incubated overnight at 37 °C and 5% CO 2 .
All peptides were synthesized by Genscript, reconstituted in DMSO at a stock concentration of 50 mg/ml and were used to pulse APCs either individually or as a mixture of peptides (peptide pools). The peptide pools consisted of 12 long peptides that corresponded exactly to the peptides encoded by the respective TMG (Supplementary Table 1 ). Autologous dendritic or B cells (APCs) were harvested, washed, resuspended at 1.0 × 10 6 cells/ml in D or B cell medium, respectively, and incubated with 10 µ g/ml of the individual peptide or the peptide pools (10 μ g/ml of each peptide), unless otherwise specified, either for 2 h or overnight at 37 °C at 5% CO 2 . Following pulsing, the APCs were centrifuged, resuspended in fresh D or B cell medium without cytokines in concentration 1 × 10 6 cells/ml and used immediately in coculture assays.
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Coculture assays: IFN-γ enzyme-linked immunospot (ELISPOT) assay, enzymelinked immunosorbent assay (ELISA) and flow cytometry for activation marker 4-1BB. Coculture conditions. T cells were incubated with peptide-pulsed or TMG-electroporated APCs at a ratio of 1:2.5 or 1:5 for dendritic or B cells, respectively. In addition, vehicle (DMSO)-pulsed APCs or T cell alone, with or without plate-bound OKT3 (1-10 μ g/ml), were used as controls. TILs were rested in complete medium (CM; RPMI 1640 medium supplemented 10% human serum, 25 mM HEPES, 2 mM l-glutamine, with or without 55 μ M β -mercaptoethanol (ThermoFisher Scientific)) with or without IL-2 (300-6,000 IU/ml) for several hours to several days before coculture. PBLs were cultured in LCM medium (AIM-V medium CTS (Gibco) complemented with 5% human serum, 25 mM HEPES buffer, 1× MEM non-essential amino acids (Corning), l-glutamine and 55 μ M β -mercaptoethanol) supplemented with 300 IU/ml IL-2. Before each coculture, the cytokine-containing medium was removed, and the TILs or PBLs were resuspended in cytokine-free medium. Typically, an equal volume (100 μ l) of T cells and APCs were mixed together for total volume of 200 μ l/well in 96-well plates. All cocultures were performed in exogenous cytokine-free medium at 37 °C and 5% CO 2 for 18-24 h. For cocultures intended to be used for sorting, the ratio of T cells to APCs was typically 1:2 to 1.0:2.5 regardless of the type of APCs. Cell sorting was carried out using the BD FACSAria IIu instrument (BD Biosciences) at the FACS facility, Surgery Branch, NCI.
IFN-γ enzyme-linked immunospot (ELISPOT) assay. IFN-γ ELISPOT assays
were performed in MultiScreen-IP filter plates (EMD Millipore). Each plate was pretreated with 50 μ l 35% or 70% ethanol/well for < 2 min, washed 4× with Ultrapure water (Quality Biological) and then coated with 10 μ g/ml of an IFN-γ capture antibody (100 μ l/well, clone: 1-D1K, Mabtech, diluted in PBS) overnight at 4 °C. Anti-CD3 antibody (clone: OKT3, 1-10 μ g/ml) was added to the positive-control wells. At the day of coculture, each plate was washed 5× with PBS and blocked with complete medium without IL-2 for at least 30 min at room temperature. After overnight coculture (18-24 h), the cells were harvested and transferred into a round-bottom 96-well plate for flow cytometry staining and analysis. Each ELISPOT plate was washed 5× with PBS containing 0.05% Tween 20 (MP Biomedicals) and then incubated for 2 h with 1 μ g/ml, 0.22-μ m filtered antihuman-IFN-γ detection antibody (clone: 7-B6-1, Mabtech, 100 μ l/well, diluted in PBS + 0.5% FBS). Next, each plate was washed 5× with PBS and incubated for 1 h with streptavidin-ALP (Mabtech, 100 μ l/well, 1:3,000 diluted with PBS + 0.5% FBS), followed by three washes with ddH 2 O and development with 0.45-μ m-filtered BCIP-NBT substrate solution (KPL, 100 μ l/well) for 5-10 min. The reaction was stopped by rinsing thoroughly with cold tap water. After they completely dried, each ELISPOT plate was scanned and counted using an ImmunoSpot plate reader and associated software (Cellular Technologies).
Flow cytometry for activation markers. T cell activation was assessed by staining for upregulation of 4-1BB (CD137) and OX40 (CD134); however, upregulation of OX40 seemed inconsistent with T cell activation, as compared to 4-1BB. Therefore, 4-1BB was used as the T cell activation marker throughout the manuscript. Specifically, following coculture, harvested cells were pelleted and resuspended in FACS buffer (PBS containing 0.5% BSA (Sigma-Aldrich) and 2 mM EDTA (Crystalgen)). The cells were surface-stained with the appropriate antibodies for 30 min, at 4 °C in the dark, followed by 2× washes with cold FACS buffer and resuspension in FACS buffer containing propidium iodide (PI; 1 μ g/ml, Sigma Aldrich). All data acquisition was performed using a BD FACSCanto I or FACSCanto II flow cytometer (BD Biosciences), and data analysis was performed using the FlowJo software (FlowJo, LLC). All of the data were gated on single (forward scatter (FSC)-H versus FSC-W, and side scatter (SSC)-H versus SSC-W), live (PI -) cells.
Enzyme-linked immunosorbent assay (ELISA).
In cocultures in which adherent cells (COS7 and HEK-CIITA) were used, the assessment of IFN-γ secretion was performed by ELISA. Briefly, flat-bottom 96-well plates were pretreated with 1 μ g/ml of a human IFN-γ capture antibody (clone: 2G1, ThermoFisher Scientific), at least 24 h before the assay, at 4 °C. At the day of the assay, the plates were blocked with 150 μ l of 4% BSA in PBS for at least 30 min at room temperature. Meanwhile, coculture supernatant was harvested or thawed, and 50 μ l of each sample was added per well, after the plate-blocking step. Each plate was incubated for 60 min, followed by three washes with ELISA buffer (PBS containing 0.05% Tween 20) and incubation for 1 h with 0.5 μ g/ml biotinylated anti-human-IFN-γ detection antibody (clone: B133.5, ThermoFisher Scientific, 50 μ l/well, diluted in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS). Each plate was then washed 3× with ELISA buffer and incubated for 30-45 min with 125 ng/ml streptavidin-horseradish peroxidase (ThermoFisher Scientific, 150 μ l/well, diluted in PBS with 4% BSA), followed by three washes with ELISA buffer. Finally, the plate was developed with TMB substrate (100 μ l/well, ThermoFisher Scientific) in the dark, and the reaction was stopped with 100 μ l/well of 0.1 M H 2 SO 4 (Sigma Aldrich). Each ELISA plate was measured using a SpectraMax 190 microplate reader (Molecular Devices) and the associate software SoftMax Pro 6.2.2 (Molecular Devices). Data analysis was performed with Microsoft Excel software.
Flow cytometry antibodies and procedures. The following human-proteinspecific flow cytometry antibodies were purchased from BD Biosciences: CD3-APC-H7 (clone: SK7), CD3-APC-Cy7 (clone: SK7), CD3-APC (clone: SK7), CD137(4-1BB)-APC (clone: 4B4-1), CD4-PE (clone: RPA-T4), CD4-PE-Cy7 (clone: SK3), CD8-PE-Cy7 (clone: RPA-T8), CD8-APC-H7 (clone: SK1), CD62L-APC (clone: DREG-56), CD45RO-FITC (clone: UCHL1), CD279(PD-1)-APC (clone MIH4), mouse IgG1κ (isotype control)-APC. The following antibodies from Beckman Coulter were also used here: TCR-Vβ 3-FITC (clone: CH92), TCR-Vβ 13.1-PE (clone IMMU 222) and TCR-Vβ 17-PE (clone: E17.5F3.15.13). For the assessment of the TCR repertoire, the Beta Mark TCR Vβ Repertoire KIT (Beckman Coulter) was used. Also, the following mouse-protein-specific flow cytometry antibodies were used: TCR-β -chain-PE (clone: H57-597, BD Biosciences) and TCR-β -chain-FITC (clone: H57-597, BD Biosciences). Standard procedures, as described above, were used for all cell-surface staining, data acquisition and analysis. For the investigation of PD-1 expression by flow cytometry, TILs (infusion product) or post-infusion peripheral blood mononuclear cells (PBMCs) were thawed and rested overnight in CM medium without cytokines before staining.
TCR identification and construction. TCR high-throughput sequencing. TRAVand TRBV-targeted high-throughput sequencing, following DNA extraction, was performed on pelleted, snap-frozen TILs, PBLs, sorted T cells or fresh tumor samples by Adaptive Biotechnologies, using the ImmunoSEQ assay platform. All TCR frequencies were calculated based only on the productive TCR rearrangements.
Single-cell RT-PCR.
The single-cell RT-PCR protocol for the identification of neoantigen-reactive TCR pairs has been previously described 19 . Briefly, 4-1BB + cells were sorted into RT-PCR buffer, following coculture with neoantigen-pulsed APCs. The reverse-transcription and first-amplification reactions were performed with the One-Step RT-PCR kit (Qiagen) and multiplex PCR with multiple Vα -and Vβ -region primers. For the second amplification reaction, the first RT-PCR products were used as templates and multiple internally nested Vα -and Vβ -region primers, with one internally nested primer for Cα -and Cβ -region each, and HotStarTaq DNA polymerase (Qiagen) were used. The PCR products were purified and sequenced by the Sanger method with an internally nested Cα -or Cβ -region primer (Beckmann Coulter).
Single-cell sequencing. Activated (4-1BB + ) T cells were sorted following stimulation with a neoantigen and subjected to the Fluidigm C1 system (Fluidigm) to prepare single-cell RNA-seq samples, according to the manufacturer's protocol. Single-cell RNA-seq samples were then sequenced by the Illumina MiSeq system (Illumina), and the data were analyzed by an in-house bioinformatics program. Paired TRAV and TRBV sequences were extracted and synthesized as follows.
Full-length TCR construction. Full-length TCR-encoding sequences were constructed by fusing the sequence encoding the CDR3 region of a putative reactive TCR (provided by sequencing analysis) with the partly missing conserved V-and J-region-encoding sequences, which were obtained from the IMGT online database (http://www.imgt.org). The sequence encoding the resulting human V-(D)-J region was fused to the modified mouse TRAC or TRBC region. The modifications in the mouse TCR constant regions were previously described 20, 21 . Use of the mouse TCR constant regions promoted pairing of the introduced TCR-encoding genes by excluding pairing with the genes encoding the endogenous TCRs and facilitated identification of the transduced T cells by flow cytometry using anti-mouse-TCR-β -chain antibodies. Sequences encoding the full-length TCRs were codon-optimized, synthesized and cloned into the MSGV1 retroviral vector (Genscript). When sequences for the TCR α -chains and β -chains were cloned into the same vector, a furin SGSG P2A linker was added between the two chains.
TCR transduction of peripheral blood T cells. Transduction of autologous or allogeneic peripheral blood T cells was conducted as has been previously described 8 . Briefly, autologous or allogeneic apheresis samples were stimulated with 50 ng/ml soluble OKT3 antibody and 300 IU/ml IL-2 for 2 d before retroviral transduction. Supernatants from transient retroviral transductions were generated by co-transfecting the retroviral packaging cell line 293GP with the TCRencoding MSGV1 plasmid(s) (1.5 μ g/well) and the envelope-encoding plasmid RD114 (0.75 µ g/well). Retroviral supernatants were collected at 24 or 48 h after transfection and used to transduce the activated T cells into retronectin-coated plates (Takara). Transduced T cells were kept in LCM medium for at least 7 d, when the transduction efficiency was examined by flow cytometry using CD3 and mouse TCR β -chain (mTCR) staining.
Minimal epitope prediction. HLA-class-I-bound epitopes were predicted using the netMHCpan 3.0 algorithm, and candidate epitopes were selected for testing based on the highest percentile ranking.
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Experimental design 1. Sample size
Describe how sample size was determined.
This was a single patient case report, therefore the sample size was 1.
Data exclusions
Describe any data exclusions.
No data were excluded from the analyses.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All attempts for replication of the results, where applicable, were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups. This is a single patient case report. No randomization was done.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis. This is a single patient case report, so there was no blinding in group allocation.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
